Reproductive biology and IVF: ovarian stimulation and luteal phase consequences

被引:166
作者
Fauser, BCJM
Devroey, P
机构
[1] Erasmus MC, Ctr Reprod Med, NL-3015 GD Rotterdam, Netherlands
[2] Vrije Univ Brussels, Univ Hosp, Ctr Reprod Med, Brussels, Belgium
关键词
D O I
10.1016/S1043-2760(03)00075-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Most clinicians working in in vitro fertilization (IVF) centers worldwide have taken for granted for more than a decade the paradigm of so-called 'controlled' ovarian hyperstimulation, using maximum stimulation by exogenous gonadotropins, together with the gonadotropin-releasing hormone (GnRH) agonist long-protocol. Potential detrimental effects of this approach with regard to oocyte quality, corpus luteum function and endometrial receptivity have been largely ignored. These factors might by themselves have a major impact on IVF outcome and should therefore be considered seriously. The recent introduction of GnRH antagonists along with the current emphasis on the need for transfer of a reduced number of embryos enables a careful re-evaluation of current IVF strategies. We can now render stimulation protocols simpler, starting with a spontaneous menstrual cycle, allowing for more subtle interference with single dominant follicle selection. Here, we discuss recent approaches to ovarian stimulation, the induction of oocyte maturation, and effects of these altered follicular phase interventions on corpus luteum function following ovarian stimulation.
引用
收藏
页码:236 / 242
页数:7
相关论文
共 67 条
  • [21] Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization
    Fauser, BC
    de Jong, D
    Olivennes, F
    Wramsby, H
    Tay, C
    Itskovitz-Eldor, J
    van Hooren, HG
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (02) : 709 - 715
  • [22] Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction?
    Fauser, BCJM
    [J]. HUMAN REPRODUCTION, 1998, 13 : 36 - 46
  • [23] Alternative approaches in IVF
    Fauser, BCJM
    Bouchard, P
    Bennink, HJTC
    Collins, JA
    Devroey, P
    Evers, JLH
    van Steirteghem, A
    [J]. HUMAN REPRODUCTION UPDATE, 2002, 8 (01) : 1 - 9
  • [24] Manipulation of human ovarian function: Physiological concepts and clinical consequences
    Fauser, BCJM
    VanHeusden, AM
    [J]. ENDOCRINE REVIEWS, 1997, 18 (01) : 71 - 106
  • [25] Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks
    Fauser, BCJM
    Devroey, P
    Yen, SSC
    Gosden, R
    Crowley, WF
    Baird, DT
    Bouchard, P
    [J]. HUMAN REPRODUCTION, 1999, 14 (11) : 2681 - 2686
  • [26] The potential value of mid-follicular phase LH
    Filicori, M
    [J]. HUMAN REPRODUCTION, 2002, 17 (02) : 517 - 518
  • [27] Luteinzing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation
    Filicori, M
    Cognigni, GE
    Taraborrelli, S
    Spettoli, D
    Ciampaglia, W
    de Fatis, CT
    Pocognoli, P
    Cantelli, B
    Boschi, S
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (01) : 337 - 343
  • [28] Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH
    Fleming, R
    Rehka, P
    Deshpande, N
    Jamieson, ME
    Yates, RWS
    Lyall, H
    [J]. HUMAN REPRODUCTION, 2000, 15 (07) : 1440 - 1445
  • [29] Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation
    Fluker, M
    Grifo, J
    Leader, A
    Levy, M
    Meldrum, D
    Muasher, SJ
    Rinehart, J
    Rosenwaks, Z
    Scott, RT
    Schoolcraft, W
    Shapiro, DB
    [J]. FERTILITY AND STERILITY, 2001, 75 (01) : 38 - 45
  • [30] FRYDMAN R, 1991, FERTIL STERIL, V56, P923